Defense of oral epithelial cells from candida by hBDs

hBD 保护口腔上皮细胞免受念珠菌侵害

基本信息

  • 批准号:
    7075771
  • 负责人:
  • 金额:
    $ 27.04万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-07-15 至 2008-05-31
  • 项目状态:
    已结题

项目摘要

Oral candidal infections are re-emerging owing to the prevalence of AIDS in the under-developed world, where highly active antiretroviral therapy (HAART) is not available, in cases where resistance to HAART develops and in misuse of antibiotics. Recent findings point to mucosal epithelial cells as the sources of antibacterial and antifungal agents, belonging to a family of small, cationic peptides called human beta-defensins (hBDs). We recently discovered a novel strategy by which F. nucleatum, a ubiquitous organism of the oral cavity, protects human oral epithelial cells (HOECs) by inducing hBDs. Since they can kill the fungal pathogen Candida albicans, act as chemoattractants towards dendritic cells (DCs), monocytes and T cells and can induce maturation of DCs and monocytes, one can surmise the importance of these agents in preventing fungal infection at mucosal surfaces, and/or controlling C. albicans replication until acquired immune cells are recruited to the local site. This proposal intends to test hypotheses emanating from the postulate that oral epithelial cells can be stimulated to produce beta-defensins that protect the host from fungal challenges at the oral mucosal barrier. Since the role of hBDs in protecting the oral mucosal epithelium from fungal biofilm growth, the mechanisms by which they are regulated when cells are confronted by a beneficial versus opportunistic organism, the presence of other HOEC derived antimicrobial peptides, or whether hBD expression is altered in HOECs as a result of HIV, have never been systematically studied, we offer the following objectives: (1) to determine the importance of hBDs against C. albicans following F. nucleatum activation in human oral epithelial cells (HOECs) from HIV- and HIV+ individuals and (2) to define HOEC responses to C. albicans challenge as regards cytokine expression and utilization of toll-like receptors and intracellular signaling pathways. . In light of the frequent adjunctive use of antibiotics and antimycotics in treating oral diseases, with the threat of microbial resistance, investigations into novel eukaryotic peptides, such as beta-defensins, are highly significant and offer the potential for future clinical promise. This novel research direction is viewed as extremely significant in leading to future studies that have potential application to oral disorders, therapuetic use, and technology development.
由于艾滋病在不发达国家的流行,口腔念珠菌感染正在重新出现,这些国家没有高效抗逆转录病毒疗法(HAART),在对HAART产生耐药性的情况下以及滥用抗生素。最近的研究结果表明,粘膜上皮细胞是抗菌和抗真菌药物的来源,属于一个小的,阳离子肽家族,称为人β -防御素(hBDs)。我们最近发现了一种新的策略,即在口腔中普遍存在的具核梭菌通过诱导hBDs来保护人类口腔上皮细胞(HOECs)。由于它们可以杀死真菌病原体白色念珠菌,作为树突状细胞(dc)、单核细胞和T细胞的化学引诱剂,并可以诱导树突状细胞和单核细胞的成熟,因此可以推测这些药物在预防粘膜表面真菌感染和/或控制白色念珠菌复制方面的重要性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

AARON WEINBERG其他文献

AARON WEINBERG的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('AARON WEINBERG', 18)}}的其他基金

Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    8462465
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    7869420
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    8527963
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    8254426
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    8070381
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Oral Mucosal Immunity in Vulnerable HIV Infected Populations
易受艾滋病毒感染人群的口腔粘膜免疫
  • 批准号:
    7680509
  • 财政年份:
    2009
  • 资助金额:
    $ 27.04万
  • 项目类别:
Fusobacterial associated beta defensin inducer
梭杆菌相关β防御素诱导剂
  • 批准号:
    8456173
  • 财政年份:
    2007
  • 资助金额:
    $ 27.04万
  • 项目类别:
Fusobacterial associated beta defensin inducer
梭杆菌相关β防御素诱导剂
  • 批准号:
    8187121
  • 财政年份:
    2007
  • 资助金额:
    $ 27.04万
  • 项目类别:
Ontogeny Of Oral Epithelial Antimicrobial Peptides
口腔上皮抗菌肽的个体发育
  • 批准号:
    7609192
  • 财政年份:
    2007
  • 资助金额:
    $ 27.04万
  • 项目类别:
Fusobacterial associated beta defensin inducer
梭杆菌相关β防御素诱导剂
  • 批准号:
    8286091
  • 财政年份:
    2007
  • 资助金额:
    $ 27.04万
  • 项目类别:

相似国自然基金

具核梭杆菌Fusobacterium nucleatum调控RIPK4促进放射性肠道损伤的机制研究
  • 批准号:
    32371290
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
具核梭杆菌(Fusobacterium nucleatum)调控circPTBP3对大肠癌发生发展的影响及机制研究
  • 批准号:
  • 批准年份:
    2022
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
慢性应激状态下肠菌Fusobacterium nucleatum与claudin-2互作致微肠漏的机制研究
  • 批准号:
    82000487
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Fusobacterium nucleatumの大腸癌細胞接着性の菌株差解明と応用
具核梭杆菌菌株差异在结肠癌细胞粘附中的阐明及应用
  • 批准号:
    24K19869
  • 财政年份:
    2024
  • 资助金额:
    $ 27.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Metabolic modulation of Fusobacterium nucleatum virulence
具核梭杆菌毒力的代谢调节
  • 批准号:
    10681729
  • 财政年份:
    2023
  • 资助金额:
    $ 27.04万
  • 项目类别:
Selective neutralization of Fusobacterium nucleatum using chicken egg antibodies and development of an oral microbiota transition method
使用鸡蛋抗体选择性中和具核梭杆菌并开发口腔微生物群转变方法
  • 批准号:
    23K09472
  • 财政年份:
    2023
  • 资助金额:
    $ 27.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Class of Chemically Modified Small RNA Inhibitors against Fusobacterium nucleatum
一类新型化学修饰小 RNA 抑制剂,抗具核梭杆菌
  • 批准号:
    10875055
  • 财政年份:
    2023
  • 资助金额:
    $ 27.04万
  • 项目类别:
歯肉縁下プラークのdysbiosis におけるFusobacterium nucleatum の役割の解明
阐明具核梭杆菌在龈下菌斑生态失调中的作用
  • 批准号:
    23K16029
  • 财政年份:
    2023
  • 资助金额:
    $ 27.04万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Advanced genetic systems for Fusobacterium nucleatum in oral and extra-oral pathologies
口腔和口腔外病理学中具核梭杆菌的先进遗传系统
  • 批准号:
    10790572
  • 财政年份:
    2023
  • 资助金额:
    $ 27.04万
  • 项目类别:
遠紫外線照射によるFusobacterium nucleatumの殺菌効果の検討
远紫外线照射对具核梭杆菌的杀菌效果检验
  • 批准号:
    22K07985
  • 财政年份:
    2022
  • 资助金额:
    $ 27.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Class of Chemically Modified Small RNA Inhibitors against Fusobacterium nucleatum
一类新型化学修饰小 RNA 抑制剂,抗具核梭杆菌
  • 批准号:
    10534754
  • 财政年份:
    2022
  • 资助金额:
    $ 27.04万
  • 项目类别:
A New Class of Chemically Modified Small RNA Inhibitors against Fusobacterium nucleatum
一类新型化学修饰小 RNA 抑制剂,抗具核梭杆菌
  • 批准号:
    10353249
  • 财政年份:
    2022
  • 资助金额:
    $ 27.04万
  • 项目类别:
Investigation of the pathophysiology of oral cancer caused by Fusobacterium nucleatum infection
具核梭杆菌感染所致口腔癌的病理生理学研究
  • 批准号:
    22K10342
  • 财政年份:
    2022
  • 资助金额:
    $ 27.04万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了